title: Reduced ligand affinity leads to an impaired function of the adenosine A2A receptor of human granulocytes in sepsis.
abstract: The enhanced release of reactive oxygen species by excessively activated polymorphonuclear leucocytes (PMN) is a key step in the pathogenesis of sepsis. Potent action of adenosine in inhibiting cytotoxic PMN functions has been documented. Recent data, however provide evidence that in sepsis a diminished capability of adenosine to inhibit the generation of oxygen radicals by PMN occurs. Here, we investigated the underlying mechanisms in an in vitro sepsis model and in PMN of sepsis patients. We report that lipopolysaccharide (LPS)-incubation of human PMN elicited the same increase in the half-maximal inhibitory concentration (IC(50)) of adenosine as observed in patients with septic shock. Coupling to adenylyl cyclase was impaired as well, as indicated by a decreased potency of adenosine to stimulate cyclic adenosine monophosphate (cAMP) accumulation. Ligand-binding studies conducted with native, LPS-stimulated PMN, and with PMN of sepsis patients revealed that, despite an increased adenosine A(2A) receptor (A(2A)R) expression, the receptor function declines due to a diminished ligand-binding affinity most likely caused by allosteric modulators within the inflammatory environment. A(2A)R function obviously is highly dependent upon the cellular environment and thus, further functional characterization of A(2A)R responses in sepsis may be a promising approach to develop new adenosine or A(2A)R agonists based therapeutic strategies.
authors.affiliation: Department of Anaesthesiology, Ludwig Maximilians University Munich, Germany.
authors.forename: Simone
authors.initials: S
authors.lastname: Kreth
authors.forename: Ines
authors.initials: I
authors.lastname: Kaufmann
authors.forename: Carola
authors.initials: C
authors.lastname: Ledderose
authors.forename: Benjamin
authors.initials: B
authors.lastname: Luchting
authors.forename: Manfred
authors.initials: M
authors.lastname: Thiel
mesh_terms: D000241:Adenosine / Q000378:metabolism*; D000262:Adenylyl Cyclases / Q000378:metabolism; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D020033:Protein Isoforms / Q000502:physiology; D017382:Reactive Oxygen Species / Q000378:metabolism; D043705:Receptor, Adenosine A2A / Q000502:physiology*; D018805:Sepsis / Q000378:metabolism*
chemical_list: D016207:Cytokines; D008070:Lipopolysaccharides; D020033:Protein Isoforms; D017382:Reactive Oxygen Species; D043705:Receptor, Adenosine A2A; D000262:Adenylyl Cyclases; D000241:Adenosine